HHS Secretary Robert F. Kennedy Jr, is a well-known vaccine critic, but it is way past time for human health to be put on a ...

With the stock currently priced at Rs 2,724.90, GlaxoSmithKline Pharmaceuticals shows significant activity in today's session ...

KNOWING where to invest your cash is difficult as there are thousands of companies to choose from. That’s why Holly Mead, a ...

Indian drugmaker GlaxoSmithKline Pharma reported its first quarterly revenue decline in more than two years on Friday, ...

The research, done in mice and in human cells, shows that a protein called STUB1 restrains the immune system’s elite ...

The number of significant shareholder protests has more than doubled so far this year compared with a year ago, with 11 FTSE ...

In addition to Barclays, Sanofi also received a Buy from J.P. Morgan’s Richard Vosser in a report issued on August 8. However, on August 5, Deutsche Bank maintained a Hold rating on Sanofi (Other OTC: ...

The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.

GlaxoSmithKline Pharmaceuticals' shares fell by 2% in Thursday's morning trade, reflecting a bearish market sentiment. The company is currently trading at Rs 2,680.10 per share.

In a report released today, Steve Scala from TD Cowen maintained a Hold rating on GlaxoSmithKline. The company’s shares closed yesterday at $37.67. Take advantage of TipRanks Premium at 50% off!

GlaxoSmithKline Pharmaceuticals Q1 net profit rises 12% to Rs 279 crore, despite slight dip in total income. Company highlights upcoming oncology drug launches.

Early-onset GI cancers diagnosed before age 50 are rising at alarming rates worldwide, underscoring the need for enhanced ...